PROBLEM TO BE SOLVED: To provide a novel therapeutic agent, a therapeutic method, a diagnostic method and the like in which findings obtained by elucidating the pathologic mechanism in patients with fibrodysplasia ossificans progressiva (FOP ) are utilized.SOLUTION: Disclosed are an agent, in proliferative disease having ALK2 aberration, characterized by inhibiting the expression of KDM6B or ANKS1B, thereby inhibiting cell proliferation to treat as well as, an in vitro diagnostic method, in cancer, characterized by investigating the abnormal expression or mutation of ANKS1B and evaluating the efficacy of a cancer therapeutic agent with mechanism of action of histone H3K27 methylation/demethylation.SELECTED DRAWING: Figure 1COPYRIGHT: (C)2017,JPO&INPIT【課題】進行性骨化性線維異形成症(FOP患者における病態メカニズムをより明らかにするとともに,得られた知見を活かした新たな治療薬や治療方法及び診断方法等の提供。【解決手段】ALK2の異常を有する増殖性疾患において,KDM6B又はANKS1Bの発現抑制により,細胞の増殖を抑制し,治療を行うことを特徴とする薬剤。並びに,癌において,ANKS1Bの異常発現または変異を調べることにより,ヒストンH3K27のメチル化・脱メチル化を作用機序とする癌治療薬剤の有効性を評価することを特徴とするインビトロ診断方法。【選択図】図1
